Vertex (NASDAQ: VERX) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table below ...
One key figure, however, indicates otherwise as sales for Journavx were at $20 million for the period, coming up $3 million ...
Investor's Business Daily on MSN
Vertex Pharma Dips Despite Quarterly Beat And Slight Guidance Book
Vertex stock dipped late Monday despite better-than-expected third-quarter metrics and a slight sales guidance boost.
TipRanks on MSN
Vertex price target lowered to $24 from $30 at BMO Capital
BMO Capital analyst Daniel Jester lowered the firm’s price target on Vertex (VERX) to $24 from $30 and keeps a Market Perform rating on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback